bioRxivImmunologyPreprint
Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment
Adeleye Oluwatosin AdeshakiniD, Hao ShiiD, S. Scott Perry, Heather SheppardiD, Phuong Nguyen, Xiang Sun, Peipei Zhou, Jean‐Yves MétaisiD, Trevor J. Cunningham, Kaveri Anil, Liqing TianiD, Vivek S. PecheiD, Mollie S. PrateriD, Deanna M. LangfittiD, Shondra M. Pruett‐MilleriD, Jason Todd YusteiniD, Giedre KrenciuteiD, Christopher C. DeRenzoiD, Hongbo ChiiD, Stephen M GottschalkiD
Abstract
Negative regulators of T cell function represent promising targets to enhance the intrinsic antitumor activity of CAR T cells against solid tumors. However, the endogenous immune ecosystem in solid tumors often represents an immunosuppressive therapeutic barrier to CAR T cell therapy, and it is currently unknown whether deletion of negative regulators in CAR T cells reshapes the endogenous immune landscape. To address this knowledge gap, we developed CAR T cells targeting B7-H3 in immune-competent osteosarcoma models and evaluated the intrinsic and extrinsic effects of deleting a potent negative regulator called Regnase-1 (Reg-1). Deletion of Reg-1 not only improved the effector function of B7-H3-CAR T cells but also endowed them with the ability to create a proinflammatory landscape characterized by an influx of IFN{gamma}-producing endogenous T cells and NK cells and a reduction of inhibitory myeloid cells, including M2 macrophages. Thus, deleting negative regulators in CAR T cells enforces a non-cell-autonomous state by creating a proinflammatory tumor microenvironment.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8+ T cell fate to enhance anti-tumor functionality
Isabelle Le Mercier, David Monteiro, … Micah J. Benson·bioRxiv·Jan 23, 2026
- An in vivo CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor model
Mattia Fumagalli, Dongjie An, … Frédéric Pendino·Molecular TherapyPeer-reviewed·Apr 4, 2026
- Acquisition of an immunosuppressive microenvironment after CAR-T therapy drives T-cell dysfunction and resistance
Marianna Ponzo, Lorenzo Drufuca, … Chiara Francesca Magnani·Journal for ImmunoTherapy of CancerPeer-reviewed·Oct 1, 2025
- Immunosuppressive tumor microenvironment of osteosarcoma
A. M. Taylor, J. Sheng, … C. C. Lau·bioRxiv·Nov 1, 2023
- STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcoma
Elizabeth P. Young, Christine A. Johnson, … Alejandro Sweet-Cordero·bioRxiv·Oct 24, 2025
- High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells
Russell W Cochrane, Rob A. Robino, … Leonardo M. R. Ferreira·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Nov 18, 2024